{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:06:36Z","timestamp":1793729196226,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":476,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jtct.2021.11.018","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T12:58:26Z","timestamp":1638795506000},"page":"104.e1-104.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-6412","authenticated-orcid":false,"given":"Takuto","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3245-1626","authenticated-orcid":false,"given":"S\u00edlvia M.","family":"Illamola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-3367","authenticated-orcid":false,"given":"Cathryn A.","family":"Jennissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy C.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9426-1292","authenticated-orcid":false,"given":"Paul J.","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5679-5533","authenticated-orcid":false,"given":"Ashish O.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janel R.","family":"Long-Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.11.018_bib0001","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing Busulfan-Based Conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2021.11.018_bib0002","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2021.11.018_bib0003","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bmt.1700994","article-title":"High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients","volume":"20","author":"Ljungman","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.018_bib0004","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/1389200215666140202214012","article-title":"Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children","volume":"15","author":"Huezo-Diaz","year":"2014","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.jtct.2021.11.018_bib0005","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbmt.2007.10.028","article-title":"High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen","volume":"14","author":"Geddes","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.018_bib0006","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":"Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.018_bib0007","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/sj.bmt.1702371","article-title":"An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease","volume":"25","author":"Bolinger","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.018_bib0008","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1399-3046.2011.01529.x","article-title":"Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients","volume":"15","author":"Malar","year":"2011","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2021.11.018_bib0009","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fphar.2020.00888","article-title":"Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population. Original Research","volume":"11","author":"Shukla","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtct.2021.11.018_bib0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/11598180-000000000-00000","article-title":"Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing","volume":"51","author":"Bartelink","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtct.2021.11.018_bib0011","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/jcph.1120","article-title":"Population pharmacokinetic analysis of busulfan in Japanese pediatric and adult HCT patients","volume":"58","author":"Kawazoe","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jtct.2021.11.018_bib0012","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FTD.0000000000000131","article-title":"Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use","volume":"37","author":"Long-Boyle","year":"2015","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jtct.2021.11.018_bib0013","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbmt.2013.08.014","article-title":"Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Research Support, N.I.H., Extramural","volume":"19","author":"Savic","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.018_bib0014","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1158\/1078-0432.CCR-11-0074","article-title":"Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children","volume":"17","author":"Trame","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2021.11.018_bib0015","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.bbmt.2019.11.014","article-title":"Reduced-toxicity (BuFlu) conditioning is better tolerated but has a higher second transplantation rate compared to myeloablative conditioning (BuCy) in children with inherited metabolic disorders","volume":"26","author":"Gupta","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.018_bib0016","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1182\/blood-2008-03-140830","article-title":"Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes","volume":"112","author":"Prasad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.11.018_bib0017","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FTD.0b013e318039b478","article-title":"Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study","volume":"29","author":"Bertholle-Bonnet","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jtct.2021.11.018_bib0018","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2125.2008.03166.x","article-title":"Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients","volume":"66","author":"Nath","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtct.2021.11.018_bib0019","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V82.3.1030.1030","article-title":"Busulfan disposition below the age of three: alteration in children with lysosomal storage disease","volume":"82","author":"Vassal","year":"1993","journal-title":"Blood"},{"issue":"Suppl 3)","key":"10.1016\/j.jtct.2021.11.018_bib0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1034\/j.1399-3046.7.s3.2.x","article-title":"Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation","volume":"7","author":"Bostrom","year":"2003","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2021.11.018_bib0021","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FTD.0b013e31824c2f60","article-title":"Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation","volume":"34","author":"Paci","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jtct.2021.11.018_bib0022","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00280-019-04001-2","article-title":"Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation","volume":"85","author":"Sun","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jtct.2021.11.018_bib0023","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/FTD.0b013e3181817428","article-title":"Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients","volume":"30","author":"Zwaveling","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jtct.2021.11.018_bib0024","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbmt.2016.10.019","article-title":"Allele-level HLA matching impacts key outcomes following umbilical cord blood transplantation for inherited metabolic disorders","volume":"23","author":"Mallhi","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2021.11.018_bib0025","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(17)30029-7","article-title":"Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis","volume":"4","author":"Admiraal","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2021.11.018_bib0026","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10928-007-9078-9","article-title":"Impact of censoring data below an arbitrary quantification limit on structural model misspecification","volume":"35","author":"Byon","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jtct.2021.11.018_bib0027","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/FTD.0b013e31826051bb","article-title":"Predictive performance of a busulfan pharmacokinetic model in children and young adults","volume":"34","author":"Bartelink","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jtct.2021.11.018_bib0028","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1078-0432.CCR-13-1960","article-title":"Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization","volume":"20","author":"McCune","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2021.11.018_bib0029","unstructured":"Busulfex (busulfan) for injection [package insert]. The U.S. Food and Drug Administration. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020954s014lbl.pdf. Accessed January 22, 2021."},{"key":"10.1016\/j.jtct.2021.11.018_bib0030","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40262-015-0277-z","article-title":"Prediction of fat-free mass in children","volume":"54","author":"Al-Sallami","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtct.2021.11.018_bib0031","first-page":"225","article-title":"Association of busulfan area under the curve with veno-occlusive disease following BMT","volume":"17","author":"Dix","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.018_bib0032","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/bmt.2015.218","article-title":"Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children","volume":"51","author":"Philippe","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.11.018_bib0033","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/psp4.12683","article-title":"Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: results from a multicenter population pharmacokinetic study","volume":"10","author":"Ben Hassine","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jtct.2021.11.018_bib0034","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/bcp.13566","article-title":"Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation","volume":"84","author":"Nava","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtct.2021.11.018_bib0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/tpj.2013.38","article-title":"The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"14","author":"Uppugunduri","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jtct.2021.11.018_bib0036","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/jhg.2013.38","article-title":"Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia","volume":"58","author":"Yee","year":"2013","journal-title":"J Hum Genet"},{"key":"10.1016\/j.jtct.2021.11.018_bib0037","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/bjh.13059","article-title":"Transplantation in inborn errors of metabolism: current considerations and future perspectives","volume":"167","author":"Boelens","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.11.018_bib0038","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/17425255.2017.1360277","article-title":"Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review","volume":"13","author":"Myers","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jtct.2021.11.018_bib0039","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/diagnostics11020273","article-title":"Epidemiology of Mucopolysaccharidoses Update","volume":"11","author":"\u00c7elik","year":"2021","journal-title":"Diagnostics (Basel)"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721014068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721014068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:02:12Z","timestamp":1763002932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721014068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2666636721014068"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.11.018","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}